A shortened adjuvant chemotherapy regimen improved outcomes for infants with unilateral pathologic high-risk retinoblastoma, according to study results.
Researchers reported improved 5-year DFS among those who received three cycles compared with those who received six cycles.
Prior studies established adjuvant therapy as an effective and important component of retinoblastoma treatment. However, evidence from head-to head trials comparing six cycles vs. three cycles of CEV chemotherapy — which consists of carboplatin, etoposide and vincristine — for treatment of enucleated unilateral